Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 3/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370796 | 0.83 | NPBWR1 (0.50) | NPBWR1MCHR1P2RX7GAA | |
| SCHEMBL15130201 | 0.79 | SMN1; SMN2 (0.48) | NPBWR1PDE1B | |
| SCHEMBL15130302 | 0.78 | NPBWR1 (0.42) | NPBWR1MCHR1PDE1APDE1BPDE1C | |
| SCHEMBL15303455 | 0.78 | ALDH1A1 (0.43) | NPBWR1GAA | |
| SCHEMBL15130262 | 0.78 | NPBWR1 (0.44) | NPBWR1MCHR1PDE1BGAA | |
| SCHEMBL15130248 | 0.76 | GRIN1 (0.44) | NPBWR1MCHR1GAAUCHL1 | |
| SCHEMBL18258722 | 0.74 | CASP3 (0.44) | — | |
| SCHEMBL15130305 | 0.73 | POLB (0.42) | NPBWR1MCHR1PDE1APDE1BPDE1C | |
| SCHEMBL15130291 | 0.72 | NPBWR1 (0.42) | NPBWR1MCHR1GAAUCHL1 | |
| SCHEMBL15130292 | 0.72 | NPBWR1 (0.42) | NPBWR1MCHR1GAAUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804870-B1 | 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-11-30 | — | — | EP | disclosed |
| US-20140349994-A1 | Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA S.A. (CH) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349994-A1 | Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors | GRM4, GRM1, GRM5 | NPBWR1 575/4885MCHR1 271/4885P2RX7 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.